How useful is the monitoring of (low molecular weight heparin therapy by anti-Xa assay? A laboratory perspective

Laboratory Hematology

Volumn 11, Issue 3, 2005, Pages 157-162

  Favaloro, Emmanuel J ^a   Bonar, Roslyn ^a   Aboud, Margaret ^a   Low, Joyce ^a   Sioufi, John ^a   Wheeler, Michael ^a   LLoyd, John ^a   Street, Alison ^a   Marsden, Katherine ^a  

^a Western Sydney Area Health Service   (Australia)

Author keywords

Anticoagulant therapy; Diagnostic practice; Hemostasis testing; Heparin monitoring; Laboratory assessment; Quality control; Survey

Indexed keywords

ENOXAPARIN; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; AUSTRALIA AND NEW ZEALAND; BLOOD SAMPLING; CLINICAL LABORATORY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DETERMINATION; DRUG MONITORING; FIBRINOGEN BLOOD LEVEL; HEMODYNAMIC MONITORING; HEPARINIZATION; HUMAN; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; QUALITY CONTROL; QUESTIONNAIRE; STANDARDIZATION; THROMBIN TIME;

DRUG MONITORING; FACTOR XA; HEMATOLOGIC TESTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; REFERENCE STANDARDS;

EID: 28044470299     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.05028     Document Type: Article

References (24)

1. Gallus AS, Coghlan DW. Heparin pentasaccharide. Curr Opin Haematol. 2002;9:422-429.
2. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Arteriosclerosis, Thrombosis & Vascular Biology. 2001;21:9-33.
3. Connors JJ. Pharmacologic agents in stroke prevention, acute stroke therapy, and interventional procedures. J Vasc Interv Radiol. 2004;15(Supplement):S87-S101.
4. Nazario R, Delorenzo LJ, Maguire GP. Treatment of venous thromboembolism. Cardiol Rev. 2002;10:249-259.
5. Hirsh J, Bates S. Clinical trials that have influenced the treatment of venous thromboembolism: A historical perspective. Ann Intern Med. 2001;134:409-417.
6. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol. 2000;111:397-406.
7. Eikelboom J, Baker R. Routine home treatment of deep vein thrombosis: Is now a reality. BMJ. 2001;322:1192-1193.
8. Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation. 2002;105:1004-1011.
9. Mackinlay N, Favaloro EJ, Arthur C, Smith J, Aboud M. A survey of heparin monitoring in Australasia. Pathology. 1996;28:343-347.
10. Bounameaux H, De Moerloose P. Is laboratory monitoring of low molecular weight heparin therapy necessary? No. J Thromb Haemost. 2004;2:551-554.
11. Harenberg J. Is laboratory monitoring of low molecular weight heparin therapy necessary? Yes. J Thromb Haemost. 2004;2: 547-550.
12. Ip BKH, Thomson AR, Moriaty HT. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular-weight heparin. Pathology. 2001;33:347-352.
13. Shojania AM. More on: is laboratory monitoring of low-molecular-weight-heparin necessary? J Thromb Haemost. 2004;2: 2276-2277.
14. Hirsch J. Laboratory monitoring of low-molecular-weight-heparin therapy. J Thromb Haemost. 2004;2:1003.
15. Hull RD. Laboratory monitoring of low-molecular-weight-heparin therapy. J Thromb Haemost. 2004;2:1004-1005.
16. Bachmann F. Laboratory monitoring of low-molecular-weight-heparin therapy. J Thromb Haemost. 2004;2:1005-1006.
17. Kearon C. Laboratory monitoring of low-molecular-weight-heparin therapy. J Thromb Haemost. 2004;2:1006-1007.
18. Fiessinger JN. Laboratory monitoring of low-molecular-weight-heparin therapy. J Thromb Haemost. 2004;2:1007.
19. Kitchen S, Iampietro R, Wolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or Danaparoid: Inter-assay variability. Thromb Haemost. 1999;82: 1289-1293.
20. Depasse F, Gilbert M, Goret V, Rolland N, Samama MM. Anti-Xa monitoring: Inter-assay variability. Thromb Haemost. 2000; 84:1122-1123.
21. Depasse F, Gerotziafas GT, Busson J, Van Dredeb P, Samama MM. Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. J Thromb Haemost. 2003;2:346-348.
22. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost. 2002;87:163-164.
23. Contact and other details available at: http://www.rcpaqap.com.au/. Last accessed by author on 19/12/2002.
24. Favaloro EJ, Bonar R, Sioufi J, et al. (on behalf of the RCPA QAP in Haematology). An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. Pathology. 2005;37:234-238.